TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00117572

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 75 mg/m2 on day 1 (induction phase); 25 mg/m2 on day 1 (chemoradiotherapy phase)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 75 mg/m2 on day 1 (induction phase); 25 mg/m2 on day 1 (chemoradiotherapy phase)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: 75 mg/m2 on day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxyurea
Description: Each cycle: 500 mg PO q 12 hours x 6 days (11 doses)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxyurea
Description: Each cycle: 500 mg PO q 12 hours x 6 days (11 doses)
Study: NCT00866190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is an oval, coated, white, scored tablet administered once daily for 14 days or on Days 1-5, 9, and 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is an oval, coated, white, scored tablet administered once daily for 14 days or on Days 1-5, 9, and 14.
Study: NCT00117572

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: 750 mg/m2/day on days 1-5 (induction phase); 600 mg/m2/day, day 0-4 (chemoradiotherapy phase)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: 750 mg/m2/day on days 1-5 (induction phase); 600 mg/m2/day, day 0-4 (chemoradiotherapy phase)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: See protocol for details
Study: NCT03767335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEN1611
Description: MEN1611 oral dose administered twice daily for a continuous 28-day cycle
Study: NCT00117572

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: See protocol for details

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: See protocol for details

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: See protocol for details
Study: NCT02797470

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: 300 mg/m2 on Day -6, as part of BEAM and R-BEAM regimens.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 100 mg/m2 BID on Days -5 through -2, as part of BEAM and R-BEAM regimens.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: VP-16: 100 mg/m2 BID on Days -5 through -2, as part of BEAM and R-BEAM regimens.
Study: NCT02724956

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Teleflex LMA Protector
Description: Pre-curved, rigid airway tube, SGAD: A next-generation, single-use laryngeal mask with a dual gastric drainage channel and pharyngeal chamber. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu aScope
Description: Flexible scope which will be introduced into airway tube and guided through the SGAD until it will be possible to view the vocal cords. Description of the maximal optical view will be measured by the Percentage of Glottic Opening (POGO).
Study: NCT03767335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab solution for infusion administered weekly via IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant solution for injection administered monthly via IM (only for HR-positive postmenopausal women)
Study: NCT02472327

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-operative support
Study: NCT04472793

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2
Description: 1. Testing weekly samples from nasal swabs to promptly diagnose acute COVID-19 infection.~2. Testing monthly serum samples to document post-viral infection.
Study: NCT00798148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131I-MIBG , Etoposide, Melphalan, Carboplatin, Autologous Peripheral Stem Cell Transplantation
Description: 131I-MIBG 12mci/kg CEM(Etoposide)=1200mg/m2 Melphalan=210mg/m2 Carboplatin=1500mg/m2 Autologous Peripheral Stem Cell Transplantation
Study: NCT02293863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHAA4549A
Description: Participants will receive a single dose of MHAA4549A by IV infusion on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHAA4549A
Description: Participants will receive a single dose of MHAA4549A by IV infusion on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Participants will receive oseltamivir capsule either 75 mg or 150 mg BID orally for minimum of 5 days. Dosage and administration should follow local prescribing information for oseltamivir.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Participants will receive oseltamivir capsule either 75 mg or 150 mg BID orally for minimum of 5 days. Dosage and administration should follow local prescribing information for oseltamivir.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oseltamivir
Description: Participants will receive oseltamivir capsule either 75 mg or 150 mg BID orally for minimum of 5 days. Dosage and administration should follow local prescribing information for oseltamivir.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single IV dose of placebo matched to MHAA4549A on Day 1
Study: NCT02797470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells
Description: Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m2 on Day -1, as part of BEAM and R-BEAM regimens.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells
Study: NCT02365194

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Prehabilitation
Description: information included in arm description

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard counseling
Description: information included in arm description
Study: NCT02470533

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: 6 fractions of 8-9Gy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: chemoembolization
Description: Up to 4 sessions
Study: NCT02784444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MSDC-0602K
Description: MSDC-0602K capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MSDC-0602K
Description: MSDC-0602K capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MSDC-0602K
Description: MSDC-0602K capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT01286935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide
Study: NCT02724956

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu aScope
Description: Flexible scope which will be introduced into airway tube and guided through the SGAD until it will be possible to view the vocal cords. Description of the maximal optical view will be measured by the Percentage of Glottic Opening (POGO).
Study: NCT01111513

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 48-hour ropivacaine infusions
Description: Patients receive 20 ml of ropivacaine 0.5 % pre-operation through femoral block catheter, followed by ropivacaine infusions from 0.1 % to 0.1 ml/kg/hour for 48 hours.
Study: NCT03745404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 5% medicated Plaster

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 5% medicated Plaster

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Plaster
Study: NCT00668850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generex Oral-lyn™
Description: Generex Oral-lyn™ spray in a split-dose fashion (half the dose immediately prior to the meal and half the dose immediately after the meal) + BID NPH insulin AM and PM as pre-randomization dose
Study: NCT01111513

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single dose ropivacaine
Description: Patients receive 20 ml of ropivacaine 0.5% pre-operation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient controlled analgesics
Description: Patient controlled analgesics alone, no femoral block
Study: NCT00262782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine i.v. (25 mg/m2/d, d1-5) q28d; max 6 cycles
Study: NCT04010435

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: high frequency (10 HZ) rTMS pulses are applied to the dorsolateral prefrontal cortex of the dominant hemisphere.
Study: NCT00668850

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular human insulin
Description: Regular human insulin 30 minutes before meals + BID NPH insulin AM and PM as pre-randomization dose.
Study: NCT03174769

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal protein
Description: Following a two week baseline assessment period, subjects will consume a diet with normal protein diet while undergoing weight loss for 12 wk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High protien
Description: Following a two week baseline assessment period, subjects will consume a diet with high protein diet while undergoing weight loss for 12 wk.
Study: NCT01286935

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03604315

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo FDG PET/CT
Study: NCT02652546

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Assess Safety
Description: Assess the safety of a 12-week course if CC-1150 in HIV-infected adults who have been on ART for greater than or equal to 1 year and have suppressed plasma viremia
Study: NCT03604315

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo \[18F\]FTT PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 Fluorthanatrace
Description: Given IV
Study: NCT02652546

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Assess Safety
Description: Assess the safety of a 12-week course if CC-1150 in HIV-infected adults who have been on ART for greater than or equal to 1 year and have suppressed plasma viremia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Effect of drug on viral load
Description: Evaluate the effect of CC-11050 on plasma HIV-1 RNA levels by both conventional and single copy assay at week 12 and over all evaluable time points

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Effect of drug on T-cell count
Description: Evaluate the effect of CC-11050 on CD4+ T cell counts and percentages at week 12 and over all evaluable time points

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Effect of drug on inflammatory biomarkers
Description: Evaluate the effect of CC-11050 on markers of markers of systemic inflammation (TNF, IL-\^, CRP, IFNg, sCD14, D-dimer) at week 12 and over all evaluable time points.
Study: NCT04135664

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: esophagectomy
Description: esophagectomy with at least two-field (thoracic-abdominal) lymphadenectomy
Study: NCT03604315

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo \[18F\]FTT PET/CT
Study: NCT04010435

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Galvanic stimulation
Description: galvanic stimulation of the vestibular apparatus
Study: NCT03118323

Intervention type: OTHER
Intervention: Questionnaire
Description: Patients are given a questionnaire with items related to personality and their willingness-to-pay for different treatment options.
Study: NCT01334489

Intervention type: DEVICE
Group type: OTHER
Intervention: Arabin Cervical Pessary
Description: The Arabin cervical pessary, which is CE-certified for preventing SPB (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC).~It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain.
Study: NCT01639131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: intravenous gemcitabine 800mg/m2 on days 1 and 8
Study: NCT03518801

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Description: psychotherapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure
Description: psychotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: active medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: non-active medication
Study: NCT02530658

Intervention type: OTHER
Intervention: Study Introduction Visit
Description: Within 5±3 weeks following arrival at SJCRH, or at the participant/family's convenience, participants will meet with a genetic counselor and clinician, provide information for a family pedigree, undergo a physical and discuss germline testing options. Study introduction materials will be provided. Families interested in the G4K study will be referred to the study nurse or other G4K member and an Informed consent visit will be scheduled.

Intervention type: OTHER
Intervention: Informed Consent Visit
Description: Within 1±3 weeks following the Study Introduction Visit, or at the participant/family's convenience, the research nurse or other study team member will consent the family and collect demographic and medical information. Participants will complete assessment questionnaires.
Study: NCT04135664

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: esophagectomy
Description: esophagectomy with at least two-field (thoracic-abdominal) lymphadenectomy

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: chemoradiation
Description: concurrent chemotherapy and radiotherapy

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: chemoradiation
Description: concurrent chemotherapy and radiotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: active surveillance
Description: No further adjuvant therapy
Study: NCT04683133

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Optical coherence tomography assessment
Description: Optical coherence tomography assessment of coronary arteries with intermediate to severe stenosis
Study: NCT01715090

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Web-based insulin titration
Study: NCT03625960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cantharidin
Description: A thin film of cantharidin is applied to the surface of the wart and to 1 millimeter area surrounding the wart. After the film dries, it is covered with an occlusive dressing for 24 hours. The patient removes the area the next day and thoroughly washes the area with soap and water. Patients return to clinic a week later.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trichloroacetic Acid
Description: Trichloroacetic acid is applied to the surface of the wart with a wooden applicator and after drying the area is washed with soap and water in an hour.
Study: NCT00591175

Intervention type: BEHAVIORAL
Intervention: Standard Care only
Description: Dentist Provided Standard Care, 3-month follow-up assessment, Clinic visit salivary cotinine test, 12-month follow-up assessment, Clinic visit salivary cotinine test

Intervention type: BEHAVIORAL
Intervention: Dental Hygienist provided counseling + Brief Questionnaire
Description: Dental Hygienist provided + Brief Questionnaire, 3-month follow-up assessment,Clinic visit salivary cotinine test, 12-month follow-up, Clinic visit salivary cotinine test assessment

Intervention type: BEHAVIORAL
Intervention: Dental Hygienist provided counseling with personalized risk communication + Brief Questionnaire
Description: Dental Hygienist provided counseling with personalized risk communication + Brief Questionnaire, 3-month follow-up assessment, Clinic visit salivary cotinine test, 12-month follow-up assessment, Clinic visit salivary cotinine test
Study: NCT01896414

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA (marine fatty acids)
Description: Subjects will be randomized to receive either EPA or placebo, four 1 gram capsules daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized to receive either EPA/ or placebo, four 1 gram capsules daily.
Study: NCT00205946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: 150 mg of bupropion administered 5 hours before fMRI scanning
Study: NCT01639131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: intravenous docetaxel 70mg/m2 on day 8 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim or Pegfilgrastim
Description: filgrastim (granulocyte colony-stimulating factor \[G-CSF\]) on days 9 through 15 or pegfilgrastim 6 mg on day 9 or 10 of each cycle
Study: NCT01921075

Intervention type: OTHER
Intervention: normal dietary behavior
Description: normal dietary behavior during examination days

Intervention type: OTHER
Intervention: Magnetic resonance spectroscopy
Description: Non-invasive diagnostic procedure
Study: NCT03851367

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sling suspension using red cord
Description: 3 weeks duration, 15 sessions, and 30 minutes a day for five consecutive days a week. Back pain, endurance of trunk muscles (flexors, extensors and side flexors), and standing posture were evaluated pre and post interventions.
Study: NCT00205946

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered 5 hours prior to fMRI scanning (randomly assigned, double blind)
Study: NCT03607149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: standard arm : calculating the dose of pemetrexed according to body surface area~experimental arm: calculation of the dose of pemetrexed as a function of creatinine clearance (CrCLCG)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: standard arm : calculating the dose of pemetrexed according to body surface area~experimental arm: calculation of the dose of pemetrexed as a function of creatinine clearance (CrCLCG)
Study: NCT02244619

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral acetaminophen
Description: Subjects randomized to the Oral acetaminophen arm will receive 2 Tylenol 500mg capsules. In this study, one arm receives an oral form of active medication and one arm receives an IV form of active medication. To keep the subject and study personnel blinded, subjects receiving Oral acetaminophen will also receive 100ml of IV Normal Saline similar to the delivery method of the IV acetaminophen arm. The Normal Saline IV placebo will be given not as an intervention but rather as a method to maintain study integrity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV acetaminophen
Description: Subjects randomized to the IV acetaminophen arm will receive Ofirmev 1000mg in 100ml Normal Saline IV plus 2 placebo capsules. In this study, one arm receives an oral form of active medication and one arm receives an IV form of active medication. To keep the subject and study personnel blinded, subjects receiving IV acetaminophen will also receive 2 placebo capsules similar to the delivery method of the oral acetaminophen arm. The placebo capsules will be given not as an intervention but rather as a method to maintain study integrity.
Study: NCT04561284

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Indigestible fiber (classified)
Description: Participants will be asked to ingest 12 grams of indigestible fiber powder per day for a period of 8 weeks. Three times daily, they will take 4 grams of powder with their meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be asked to ingest 6 grams of placebo powder per day for a period of 8 weeks. Three times daily, they will take 2 grams of powder with their meal.
Study: NCT05469152

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ds-MCE and EGD
Description: Procedure of ds-MCE: The ds-MCE system mainly consists of two parts: the NaviCam magnetic capsule endoscopy guidance system and the detachable string part. The capsule, which is partially enclosed within the sleeve, can be actively moved in the esophagus through the control of string. Investigator can examine the entire esophagus several times under real time views. The capsule then could be detached from the string system through injecting air into the hollow string with the syringe after completing the examination of esophagus. Then, the examination of stomach under magnetic control and small bowel under the natural action of peristalsis follows.~Procedure of EGD: The EGD will be performed using conventional upper gastrointestinal video endoscopy, according to the standard procedure at individual centers. EGD will be performed within 48 hours after ds-MCE procedure and usually during the same endoscopic session.
Study: NCT02866318

Intervention type: DEVICE
Intervention: Echocardiography
Study: NCT03426449

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: posterolateral sphincterotomy
Description: Fissurectomy and limited division of internal anal sphincter at 5 o'clock position for 8-10 mm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lateral sphincterotomy
Description: Fissurectomy and limited division of internal anal sphincter at 3 o'clock position for 8-10 mm